Early discontinuation and suboptimal dosing of prazosin: A potential missed opportunity for veterans with posttraumatic stress disorder

Journal of Clinical Psychiatry

Volumn 76, Issue 5, 2015, Pages e639-e644

  Alexander, Bruce ^a   Lund, Brian C ^a   Bernardy, Nancy C ^b   Christopher, Melissa L D ^c   Friedman, Matthew J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL CENTER FOR PTSD   (United States)

^c Academic Educators for Mental Health Initiatives VISN 21 VISN 22   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG UTILIZATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT WITHDRAWAL; VETERAN; MEDICATION COMPLIANCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; STRESS DISORDERS, POST-TRAUMATIC; UNITED STATES;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRAZOSIN; STRESS DISORDERS, POST-TRAUMATIC; UNITED STATES; VETERANS;

EID: 84932101553     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09057     Document Type: Article

References (37)

1. Lund BC, Bernardy NC, Alexander B, et al. Declining benzodiazepine use in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):292-296.
2. Department of Veterans Affairs, Department of Defense. Clinical practice guideline for management of post-traumatic stress, version 1.0. http://www.healthquality.va.gov/ptsd/ptsd-full.pdf. Published January 2004. Accessed March 7, 2015.
3. Department of Veterans Affairs, Department of Defense. Clinical practice guideline for management of post-traumatic stress, version 2.0. http://www.healthquality.va.gov/guidelines/MH/ptsd/. Published October 2010. Accessed March 7, 2015.
4. Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004;161(suppl):3-31.
5. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994;55(12):517-522.
6. Hertzberg MA, Feldman ME, Beckham JC, et al. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry. 2000;12(2):101-105.
7. Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68(5):711-720.
8. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine v placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry. 2002;181(4):315-320.
9. Aurora RN, Zak RS, Auerbach SH, et al; Standards of Practice Committee; American Academy of Sleep Medicine. Best practice guide for the treatment of nightmare disorder in adults. J Clin Sleep Med. 2010;6(4):389-401.
10. Kung S, Espinel Z, Lapid MI. Treatment of nightmares with prazosin: a systematic review. Mayo Clin Proc. 2012;87(9):890-900.
11. Bernardy NC, Lund BC, Alexander B, et al. Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):297-303.
12. Harpaz-Rotem I, Rosenheck RA. Tracing the flow of knowledge: geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs. Arch Gen Psychiatry. 2009;66(4):417-421.
13. Raskind MA, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013;170(9):1003-1010.
14. Byers MG, Allison KM, Wendel CS, et al. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol. 2010;30(3):225-229.
15. Miller LJ. Prazosin for the treatment of posttraumatic stress disorder sleep disturbances. Pharmacotherapy. 2008;28(5):656-666.
16. Abrams TE, Lund BC, Bernardy NC, et al. Aligning clinical practice to PTSD treatment guidelines: medication prescribing by provider type. Psychiatr Serv. 2013;64(2):142-148.
17. Bernardy NC, Lund BC, Alexander B, et al. Gender differences in prescribing among veterans diagnosed with posttraumatic stress disorder. J Gen Intern Med. 2013;28(suppl 2):S542-S548.
18. Lund BC, Bernardy NC, Vaughan-Sarrazin M, et al. Patient and facility characteristics associated with benzodiazepine prescribing for veterans with PTSD. Psychiatr Serv. 2013;64(2):149-155.
19. Lund BC, Charlton ME, Steinman MA, et al. Regional differences in prescribing quality among elder veterans and the impact of rural residence. J Rural Health. 2013;29(2):172-179.
20. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the US Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry. 2008;69(6):959-965.
21. Gravely AA, Cutting A, Nugent S, et al. Validity of PTSD diagnoses in VA administrative data: comparison of VA administrative PTSD diagnoses to self-reported PTSD Checklist scores. J Rehabil Res Dev. 2011;48(1):21-30.
22. Lund BC, Abrams TE, Gravely AA. Rebuttal to Gravely et al: validity of PTSD diagnoses in VA administrative data: comparison of VA administrative PTSD diagnoses to self-reported PTSD Checklist scores. J Rehabil Res Dev. 2011; 48(1):21-30. available from: http://www.rehab.research.va.gov/jour/11/481/pdf/gravely.pdf.
23. J Rehabil Res Dev. 2011;48(5):vii-ix.
24. Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens (Greenwich). 2010;12(12):927-934.
25. Lund BC, Ernst ME. The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans. J Clin Hypertens (Greenwich). 2012;14(9):623-629.
26. Raskind MA, Dobie DJ, Kanter ED, et al. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry. 2000;61(2):129-133.
27. Spoormaker VI, Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? Sleep Med Rev. 2008;12(3):169-184.
28. Leskin GA, Woodward SH, Young HE, et al. Effects of comorbid diagnoses on sleep disturbance in PTSD. J Psychiatr Res. 2002;36(6):449-452.
29. Mellman TA, Kulick-Bell R, Ashlock LE, et al. Sleep events among veterans with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995;152(1):110-115.
30. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-934.
31. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology. 2000;42(2):69-81.
32. Raskind MA, Thompson C, Petrie EC, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry. 2002;63(7):565-568.
33. Germain A, Richardson R, Moul DE, et al. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans. J Psychosom Res. 2012;72(2):89-96.
34. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371-373.
35. Taylor FB, Lowe K, Thompson C, et al. Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry. 2006;59(7):577-581.
36. Chapman N, Chen CY, Fujita T, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens. 2010;28(9):1796-1803.
37. Pool JL, Kirby RS. Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int UrolNephrol. 2001;33(3):407-412.